Test Price
4,600 AED✅ Home Collection Available
Oncomine™ Myelodysplastic Syndrome (MDS) Panel Test in UAE | 4600 AED | DHA Licensed Laboratory
Executive Summary & Core Metrics
- Diagnostic Accuracy: Analytic sensitivity exceeding 99.9% through ISO 9001:2015-certified next-generation sequencing (NGS) workflow (certificate INT/EGQ/2509DA/3139).
- Home Collection Service: VIP mobile phlebotomy for EDTA whole blood samples, temperature-controlled cold-chain transport (refrigerated, never frozen), available daily 8 AM – 11 PM.
- Post-Result Counseling: Complimentary telephone consultation with a Consultant Medical Geneticist to correlate genomic findings with clinical history, in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Insurance Coverage: Instant verification via WhatsApp (+971 54 548 8731) across 50+ UAE insurance providers; direct billing available.
Test Overview & Methodology
The Oncomine MDS Panel is a comprehensive NGS assay that interrogates over 25 critical genes (including SF3B1, TET2, ASXL1, SRSF2, DNMT3A, RUNX1, TP53) recurrently mutated in myelodysplastic syndromes. It provides actionable genomic insights for accurate subclassification, risk stratification, and selection of targeted or epigenetic therapies in patients with suspected or confirmed MDS.
This panel detects single-nucleotide variants, insertions/deletions, and splice site mutations at variant allele frequencies as low as 5%, enabling early identification of clonal evolution and therapeutic targets such as IDH1/2 and FLT3.
| Feature | Oncomine MDS Panel | Standard Karyotyping / FISH |
|---|---|---|
| Methodology | Illumina-based NGS with VAF quantification | Chromosomal banding or fluorescence in-situ hybridization |
| Mutation Coverage | >25 genes; SNVs, indels, splice site mutations | Limited to large deletions/duplications (>10 Mb) and specific translocations |
| Clinical Sensitivity | 85–90% for MDS-associated mutations (detection down to 5% VAF) | 40–50% for MDS; fails to detect submicroscopic lesions |
| Turnaround Time | Batch reporting: 15–30 days (cut-offs: 1st & 16th monthly) | 7–10 days (limited actionable data) |
| Therapeutic Guidance | Directs IDH1/2, FLT3, TP53-specific therapies; IPSS-M molecular risk | IPSS-R cytogenetic risk only |
Physician Insight & Safety Protocols
“This NGS assay deciphers the molecular architecture of myelodysplasia, enabling prognosis beyond morphology. Genomic data must be correlated with bone marrow blast count, cytopenias, and full clinical history. Always follow your consultant’s integrated assessment before making any treatment decisions.”
Clinical Medication Advisory
Do not discontinue any prescribed medication (e.g., azacitidine, decitabine, lenalidomide) without explicit instruction from your treating hematologist. Self-discontinuation can accelerate disease progression or trigger transformation to acute leukemia.
Exclusion Criteria & Emergency Red Flags
- Unsuitable samples: Hemolyzed, clotted, frozen, or collected in non-EDTA tube. Sample must be refrigerated, never frozen.
- Recent blood transfusion: Wait at least 10 days post-transfusion to avoid donor DNA interference (when testing peripheral blood).
- Active chemotherapy: Collection immediately after cytotoxic therapy may yield low cellularity; consult your physician.
- Consent: Mandatory signature on NGS Test Requisition Form (Form 40). Minors require parental/guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Seek emergency care if you experience: sudden high-grade fever (>38.5°C), uncontrolled bleeding, petechiae, or acute shortness of breath. These may indicate transformation to acute leukemia or severe cytopenia.
Patient FAQ & Clinical Guidance
1. What is the clinical purpose of the Oncomine MDS Panel and how does it affect my treatment?
Answer: The Oncomine MDS Panel identifies somatic mutations in genes such as SF3B1, TET2, ASXL1, and TP53 to refine your diagnosis, predict progression to acute myeloid leukemia, and guide targeted or epigenetic therapy. By uncovering specific mutations, your hematologist can select medications such as lenalidomide for del(5q) or IDH inhibitors, and estimate prognosis using the IPSS-M molecular score.
2. How is the test performed and what is the expected turnaround time?
Answer: A minimally invasive EDTA whole blood draw is collected at your home by our ISO-certified phlebotomist between 8 AM and 11 PM, transported refrigerated without freezing, and processed in batches on the 1st and 16th of each month. Results are reported by the 15th and 30th respectively. You must complete the NGS Test Requisition Form (Form 40) prior to collection.
3. Is the test covered by insurance and how is my genomic data protected?
Answer: We provide direct billing verification via WhatsApp to over 50 UAE insurers. Your genomic data is safeguarded under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) with encrypted storage and access restricted to your authorized physician. Send a message to +971 54 548 8731 for confirmation of coverage; most major policies cover NGS for MDS when medically indicated.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genomic and personal data are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, data minimization, and encryption standards are enforced at every stage.
Clinical Safety: Sample collection, handling, and reporting follow the clinical liability framework of Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring full traceability and patient rights protection.
Clinical & Logistical Metadata
| Test Name | Oncomine™ Myelodysplastic Syndrome (MDS) Panel |
| Price (AED) | 4,600 AED |
| Turnaround Time | 15–30 days (batch processing: cut-offs 1st & 16th monthly) |
| Sample Type / Matrix | EDTA whole blood (preferred) or bone marrow aspirate |
| Methodology Used | Next-Generation Sequencing (NGS) – Illumina platform, targeted amplicon-based library preparation |
| ICD-10-CM Code | D46.9 (Myelodysplastic syndrome, unspecified) |
| LOINC Code | 98591-2 (Myelodysplastic syndrome panel - Blood or Tissue by NGS) |
| DHA Facility License & Address | License #1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians